SOHO 2023 | Latest updates in the treatment of LR-MDS: COMMANDS and IMerge trials
Uwe Platzbecker, MD, University of Leipzig, Leipzig, Germany, discusses recent updates in the treatment of lower-risk myelodysplastic syndromes (LR-MDS), highlighting the FDA’s approval of luspatercept as a first-line therapy based on results from the Phase III COMMANDS study (NCT03682536). Prof. Platzbecker also comments on the efficacy of imetelstat in patients with LR-MDS with high transfusion burden, as demonstrated in the Phase III IMerge study (NCT02598661). Additionally, Prof. Platzbecker mentions roxadustat, a HIF inhibitor, which did not meet the primary endpoint in a recent, unpublished, Phase III trial (NCT03263091). This interview took place at the Eleventh Annual Meeting of the Society of Hematologic Oncology (SOHO 2023) held in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Grant support, paid to GWT-TUD, from Amgen; lecture fees and grant support, paid to the University of Leipzig, from Amgen; fees for serving on a steering committee, consulting fees, and travel support from Bristol Myers Squibb; grant support, paid to GWT-TUD, from Janssen Biotech; grant support, paid to University Dresden, from Merck and Novartis; lecture and consulting fees from Novartis; and consulting fees from AbbVie, Curis, and Geron.
